Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05967689
Registration number
NCT05967689
Ethics application status
Date submitted
11/07/2023
Date registered
1/08/2023
Date last updated
17/05/2024
Titles & IDs
Public title
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Query!
Scientific title
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.
Query!
Secondary ID [1]
0
0
2023-503865-48
Query!
Secondary ID [2]
0
0
TAS6417-201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REZILIENT2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - TAS6417
Experimental: Cohort A ("prior ex20ins treatment") - Cohort A ("prior ex20ins treatment") participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
Experimental: Cohort B ("1st line treatment") - Cohort B participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
Experimental: Cohort C ("active brain mets") - Cohort C participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
Experimental: Cohort D ("other uncommon EGFRmt"). - Cohort D participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
Treatment: Drugs: TAS6417
Oral tablets/capsules
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
All Cohorts: objective response rate (ORR)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to approximately 2 years
Query!
Secondary outcome [1]
0
0
All Cohorts: The rate and severity of treatment emergent AEs
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to approximately 2 years
Query!
Secondary outcome [2]
0
0
All Cohorts: Overall Survival (OS)
Query!
Assessment method [2]
0
0
Antitumor activity is assessed by response evaluation criteria RECIST 1.1 by measuring
Query!
Timepoint [2]
0
0
Up to approximately 2 years
Query!
Secondary outcome [3]
0
0
All Cohorts: Disease control rate (DCR)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to approximately 2 years
Query!
Secondary outcome [4]
0
0
All Cohorts: Duration of response (DoR)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to approximately 2 years
Query!
Secondary outcome [5]
0
0
Progression-free survival (PFS)
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to approximately 2 years
Query!
Secondary outcome [6]
0
0
Cohort C: Intracranial (i) Overall Response Rate (iORR)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to approximately 2 years
Query!
Secondary outcome [7]
0
0
Cohort C: intracranial duration of complete response (iDCR)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to approximately 2 years
Query!
Secondary outcome [8]
0
0
Cohort C: intracranial duration of Response (iDoR)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Up to approximately 2 years
Query!
Secondary outcome [9]
0
0
All Cohorts: Pharmacokinetic (PK) parameter
Query!
Assessment method [9]
0
0
Minimum Plasma Concentration (Cmin)
Query!
Timepoint [9]
0
0
Up to approximately 2 years
Query!
Eligibility
Key inclusion criteria
1. Written informed consent
2. =18 years of age (or meets the country's regulatory definition of legal adult age,
whichever is greater
3. Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the
following criteria:
Cohort A patients:
- Documented EGFR ex20ins mutation status, as determined by local testing performed
at a CLIA certified (US) or locally certified laboratory (outside the US).
- Progressed on or after systemic therapy with an agent targeting ex20ins, either
alone or in combination with standard platinum-based chemotherapy for the
treatment of advanced disease. Patients who discontinued previous treatment due
to unacceptable toxicity are eligible.
- Patients with brain metastasis must be neurologically stable. Patients must have
received CNS-directed therapy and have no evidence of progression for at least 4
weeks after CNS-directed treatment, as ascertained by clinical examination and
brain imaging (MRI or CT scan) during the screening period, and they must be on a
stable or decreasing dose of corticosteroids and/or anti-convulsant medications
for at least 2 weeks prior to the first dose of study treatment. Patients with
history of uncontrolled seizures or leptomeningeal disease are not eligible.
Cohort B patients:
- Documented EGFR ex20ins mutation status, as determined by local testing performed
at a CLIA certified (US) or locally certified laboratory (outside the US).
- Not received prior systemic therapy for locally advanced or metastatic disease.
Prior adjuvant/neoadjuvant treatment for early-stage disease must have been
completed >6 months prior to the first dose of study treatment.
- Patients with brain metastasis must be neurologically stable. Patients must have
received CNS-directed therapy and have no evidence of progression for at least 4
weeks after CNS-directed treatment, as ascertained by clinical examination and
brain imaging (MRI or CT scan) during the screening period, and they must be on a
stable or decreasing dose of corticosteroids and/or anti-convulsant medications
for at least 2 weeks prior to the first dose of study treatment. Patients with
history of uncontrolled seizures or leptomeningeal disease are not eligible.
Cohort C patients:
- Documented EGFR ex20ins mutation status, as determined by local testing performed
at a CLIA certified (US) or locally certified laboratory (outside the US).
- Presence of brain metastasis(es), which may be measurable or nonmeasurable by
RANO-BM criteria, characterized as one of the following:
- Newly diagnosed and/or progressive brain metastasis (es) not subjected to
CNS-directed therapy, OR
- Leptomeningeal disease (LMD) confirmed by a positive cerebrospinal fluid
cytology, or unequivocal radiographic and/or clinical determination.
Cohort D patients:
- Documented other non-ex20ins uncommon single or compound EGFRmt status, as
determined by local testing performed at a CLIA certified (US) or locally
certified laboratory (outside the US). A list of eligible mutations will be
provided in a separate manual.
- Patients with brain metastasis must be neurologically stable. Patients must have
received CNS-directed therapy and have no evidence of progression for at least 4
weeks after CNS-directed treatment, as ascertained by clinical examination and
brain imaging (MRI or CT scan) during the screening period, and they must be on a
stable or decreasing dose of corticosteroids and/or anti-convulsant medications
for at least 2 weeks prior to the first dose of study treatment. Patients with
history of uncontrolled seizures or leptomeningeal disease are not eligible.
4. Measurable disease per RECIST 1.1.
5. Archival tumor tissue available for submission, with minimum quantity sufficient to
evaluate EGFRmt status and, where possible, other biomarkers (details provided in a
laboratory manual). Patients with insufficient tissue may be eligible following
discussion with the sponsor.
6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17. Adequate
organ function, as defined by the hematologic, renal and hepatic laboratory values
4. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior
to administration of the first dose of study treatment. Female patients are not considered
to be of childbearing potential if they are post-menopausal (no menses for 12 months
without an alternative medical cause) or permanently sterile (hysterectomy, bilateral
salpingectomy, or bilateral oophorectomy).
5. Both males and females of reproductive potential must agree to use effective birth
control during the study prior to the first dose of study drug and for 6 months after the
last dose of study treatment.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patient is currently receiving an investigational drug in a clinical trial or
participating in any other type of medical research judged to be scientifically or
medically incompatible with this study.
2. Has received any of the following within the specific time frame specified:
1. Patient has received Zipalertinib (TAS6417/CLN081) at any time
2. Thoracic radiotherapy =28 days or palliative radiation =14 days prior to the
first dose of study treatment
3. Anticancer immunotherapy =28 days prior to the first dose of study treatment
4. Major surgery (excluding placement of vascular access) =28 days prior to the
first dose of study treatment.
3. Have any unresolved toxicity of Grade =2 from previous anticancer treatment, except
for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable
Grade 2 toxicities may be allowed to enroll after agreement between the investigator
and Sponsor.
4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any
grade), or evidence of clinically active interstitial lung disease.
5. Impaired cardiac function or clinically significant cardiac disease including any of
the following:
1. History of congestive heart failure (CHF) Class III/IV according to the New York
Heart Association (NYHA) Functional Classification (Appendix A)
2. Serious cardiac arrhythmias requiring treatment.
3. Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).
6. Is unable to swallow tablets/capsules or has any disease or condition that may
significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory
bowel disease, malabsorption syndrome, or prior gastric/bowel resection).
7. History of another primary malignancy =2 years prior to the date of first dose of
study treatment unless at least one of the following criteria are met:
1. Adequately treated basal or squamous cell carcinoma of the skin
2. Cancer of the breast or cervix in situ
3. Patients with previously treated malignancy if all treatment for that malignancy
was completed at least 2 years prior to first dose and no evidence of disease
4. Patients with concurrent malignancy clinically stable and not requiring
tumor-directed treatment
8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that
is not controlled with treatment.
9. History of COVID-19 infection within 4 weeks prior to enrolment and/or has persistent
clinically significant pulmonary symptoms related to prior COVID-19 infection.
10. Active bleeding disorders.
11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in
structure or class.
12. Is pregnant or lactating.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/07/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
20/10/2025
Query!
Actual
Query!
Sample size
Target
160
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,WA
Query!
Recruitment hospital [1]
0
0
Bankstown-Lidcombe Hospital - Bankstown
Query!
Recruitment hospital [2]
0
0
GenesisCare - North Shore - Saint Leonards
Query!
Recruitment hospital [3]
0
0
Joondalup Health Campus - Joondalup
Query!
Recruitment postcode(s) [1]
0
0
2200 - Bankstown
Query!
Recruitment postcode(s) [2]
0
0
2065 - Saint Leonards
Query!
Recruitment postcode(s) [3]
0
0
6027 - Joondalup
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Nevada
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New Jersey
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Tennessee
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Virginia
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Wisconsin
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Quebec
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Brampton
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Aslace
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Basse-Normandie
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Ile-de-France
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Limousin
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Loire-Atlantique
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Nouvelle-Aquitaine
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Provence Alpes Cote d´Azur
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Rhone-Alpes
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Val-de-Marne
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Île-de-France
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Baden-Wuerttemberg
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Hamburg (Hansestadt)
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Hassen
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Hessen
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Nordrhein-Westfalen
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
SAchsen
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
München
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Regensburg
Query!
Country [34]
0
0
Hong Kong
Query!
State/province [34]
0
0
Hong Kong Island
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Florence
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Forli-Cesena
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Ravenna
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Torino
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Catania
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Cremona
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Genova
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Milan
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Modena
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Parma
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Piacenza
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Roma
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Aiti
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Hukuoka
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Miyagi
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Osaka
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Sizuoka
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Tiba
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Tokyo
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Niigata
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Okayama
Query!
Country [56]
0
0
Korea, Republic of
Query!
State/province [56]
0
0
Gyeonggi-do
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Gyeonggi-Do
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Gyeongsangnamdo [Kyongsangnam-do]
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]
Query!
Country [60]
0
0
Korea, Republic of
Query!
State/province [60]
0
0
Jeollanam-do
Query!
Country [61]
0
0
Korea, Republic of
Query!
State/province [61]
0
0
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Barcelona
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
La Coruña
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Malaga
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Jaén
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
Madrid
Query!
Country [67]
0
0
Turkey
Query!
State/province [67]
0
0
Ankara
Query!
Country [68]
0
0
Turkey
Query!
State/province [68]
0
0
Diyarbakir
Query!
Country [69]
0
0
Turkey
Query!
State/province [69]
0
0
Istanbul
Query!
Country [70]
0
0
Turkey
Query!
State/province [70]
0
0
Adana
Query!
Country [71]
0
0
Turkey
Query!
State/province [71]
0
0
Edirne
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
England
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Taiho Oncology, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in patients
with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations and other
mutations.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05967689
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Taiho Oncology, INC
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
609-250-7336
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05967689
Download to PDF